Yasheng Pharmaceuticals has also landed | JIANZHI Research

One step closer to regular profitability.

wallstreetcnAug 23 01:14 ET

WuXi AppTec's joint venture, Pharmapace, has gained benefits from the ADC industry. | Jianzhi Research

Net profit increased by 175% year-on-year, exceeding expectations, but the market's extreme pessimism has not yet been eliminated.

wallstreetcnAug 21 02:17 ET

The growth rate of all channels of dressing in the second half of the year may be slightly lower than that in the first half. Juzi Biotech stated that it will continue to expand the number of terminal stores. Earnings conference coverage.

At the earnings conference, Juzi Biotech predicted that products such as wrinkle fillers may obtain registration certificates in the first quarter of next year. The company's secretary, Yan Yubo, stated that due to the impact of online growth, the overall growth rate of all channels of dressings may be slightly lower than the first half of the year. The company's CFO, Zhang Huijuan, expects that the growth rate in the CS/KA channel will further slow down in the second half of the year.

cls.cnAug 20 02:04 ET

Zai Lab Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results. Also, the Company Said It Expects Substantial Topline Growth and Path to Achieve Profitability by the End of 2025.

BenzingaAug 7 08:28 ET

Zai Lab Q2 2024 GAAP Loss Per ADS $(0.82) Misses $(0.70) Estimate, Sales $100.504M Beat $93.136M Estimate

BenzingaAug 6 16:15 ET

WuXi AppTec mid-year analysis: Biomedical industry recovery is already underway | Jian Zhi Research

Looking at the mid-year reports from CXO leaders such as WuXi AppTec, IQVIA, and Lonza, hand orders are exceeding expectations. Among them, WuXi AppTec's new hand order amount (excluding COVID-19 business) increased by 33.2%, far beyond the market expectations. The recovery trend of overseas biotech companies has already emerged.

wallstreetcnJul 29 23:40 ET